Crystallography grade
IGFBP4
Spezies: Human
Wirt: Insektenzellen
Recombinant
>95 % as determined by SDS PAGE, Size Exclusion Chromatography and Western Blot.
WB, SDS, ELISA, Crys
IGFBP4
Spezies: Ratte
Wirt: Escherichia coli (E. coli)
Recombinant
> 95 %
WB, SDS, Imm, PC
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Reconstituted in ddH2O or PBS at 100 μg/mL.
Buffer
Lyophilized after extensive dialysis against PBS.
Lagerung
-80 °C
Informationen zur Lagerung
Lyophilized recombinant human IGF-BP-4 remains stable up to 6 months at -80 °C from date of receipt. Upon reconstitution, human IGF-BP-4, His should be stable up to 1 week at 4 °C or up to 2 months at -20 °C.
Haltbarkeit
6 months
Target
IGFBP4
(Insulin-Like Growth Factor Binding Protein 4 (IGFBP4))
Andere Bezeichnung
Insulin-Like Growth Factor-Binding Protein 4 (IGF-BP-4) (IGFBP4 Produkte)
Insulin-like growth factor-binding protein 4 (IGF-BP-4), also known as IBP-4, is a secreted glycoprotein belonging to the IGFBP family. IGF-BP-4 is produced by osteoblasts, epidermis, ovarian follicles and other tissues. It binds both insulin-like growth factor (IGF) I and II, and it circulates in the plasma in both glycosylated and non-glycosylated forms. IGF-BP-4 prolongs the half-life of the IGFs and has been shown to inhibit or stimulate the growth-promoting effects of the IGFs. Pregnancy Associated Plasma Protein A (PAPP-A) proteolytically cleaves IGF-BP-4 and reduces its affinity to bind IGFs, and thus serves as an important regulator of IGF-BP-4 function. Synonyms: Insulin-like Growth Factor-Binding Protein 4, IBP-4, HT29-IGF-BP, colon cancer cell growth inhibitor